Polycarbophil
Identification
- Generic Name
- Polycarbophil
- DrugBank Accession Number
- DB09311
- Background
Polycarbophil calcium is a synthetic polymer manufactured from the cross-linking of polyacrylic acid with divinyl glycol and a calcium counter-ion. Polycarbophil calcium is a stool stabilizer used to treat constipation. This drug may also be used to help relieve the symptoms of irritable bowel syndrome or diarrhea. Less gas and bloating compared to psyllium laxative products, but can cause heartburn, and belly cramps. It is insoluble in water, dilute acids, and dilute alkali. The material possesses exceptionally high water-binding capacity. is not absorbed, does not interfere with the activity of digestive enzymes or intestinal absorption, possesses satisfactory stability, is physiologically inert, and does not cause gastrointestinal irritation.
- Type
- Small Molecule
- Groups
- Experimental
- Synonyms
- Policarbofila
- Polycarbofil
- Polycarbophil
- Polycarbophile
- Polycarbophilum
- External IDs
- WL 140
- WL-140
Pharmacology
- Indication
Polycarbophil is used to treat constipation and to help maintain regular bowel movements.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Relieves constipation or diarrhea associated with bowel disorders and acute nonspecific diarrhea.
- Mechanism of action
It is known as a bulk-forming laxative. It increases the bulk in the stool, an effect that helps to cause movement of the intestines. It also works by increasing the amount of water in the stool, making the stool softer and easier to pass.
- Absorption
Calcium polycarbophil is not absorbed from the intestine.
- Volume of distribution
Calcium polycarbophil is not absorbed from the intestine.
- Protein binding
Calcium polycarbophil is not absorbed from the intestine.
- Metabolism
Polycarrbophil calcium is not metabolized and has limited hydrophilic activity in acidic environments.
- Route of elimination
Excreted in feces.
- Half-life
Calcium polycarbophil is not absorbed from the intestine.
- Clearance
Calcium polycarbophil is not absorbed from the intestine.
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
The LD50 of calcium polycarbophil in young adult rats approximated 20 g/kg.
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAcetazolamide The risk or severity of dehydration can be increased when Acetazolamide is combined with Polycarbophil. Aclidinium The therapeutic efficacy of Polycarbophil can be decreased when used in combination with Aclidinium. Alfentanil The therapeutic efficacy of Polycarbophil can be decreased when used in combination with Alfentanil. Alloin The risk or severity of adverse effects can be increased when Polycarbophil is combined with Alloin. Amantadine The therapeutic efficacy of Polycarbophil can be decreased when used in combination with Amantadine. - Food Interactions
- Not Available
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- International/Other Brands
- Fibercon / Mitrolan
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Humans and other mammals
Chemical Identifiers
- UNII
- W25LM17A4W
- CAS number
- 9003-97-8
References
- General References
- External Links
- KEGG Drug
- D03306
- PubChem Substance
- 347910435
- Wikipedia
- Polycarbophil_calcium
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Recruiting Supportive Care Female Breast Cancer / Long-Term Survivors / Postmenopausal Syndrome / Vulvo Vaginal Atrophy 1 Not Available Completed Treatment Type 2 Diabetes Mellitus 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Tablet Tablet, chewable Oral Granule 34.72 % Tablet 625 MG Tablet, chewable Oral 625 MG - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
- Not Available
- Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
- Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Drug created at November 16, 2015 21:57 / Updated at March 18, 2024 16:48